Skip to content

Neoss Implant System 64082Recalls & reported problems

Neoss AB · NeoGen Cape Spacer 0.7 mm, Neoss NP · Class 2

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 05060440335556), received between Aug 21, 2024 and Aug 21, 2024 — classified as 1 injury.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 1 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem1

Patient problems

  • Hemorrhage/Blood Loss/Bleeding1
  • Vomiting1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryAug 21, 2024Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    ACCORDING TO THE REPORTER, THE PATIENT DEVELOPED A MAJOR BLEED FOLLOWING RADIO FREQUENCY ABLATION TREATMENT ON THE (B)(6) PRESENTED TO HOSPITAL WITH C/O VOMITING BLOOD (ABOUT 1 PINT) A WEEK AFTER HAVING HALOTHERAPY. ALSO, C/O FEELING SHORT OF BREATH AND BEING NAUSEOUS, WITH SOME EPIGASTRIC PAIN, AND HAVING BLACK STOOLS. ON EXAMINATION HE WAS QUITE PALE, AND HEMODYNAMICALLY UNSTABLE. PATIENT WAS RESUSCITATED WITH BLOOD AND PLASMA TRANSFUSION AND WAS TREATED WITH IV PPI AND WAS TAKEN FOR URGENT OGD, WHICH SHOWED A LARGE UGI BLEED SECONDARY TO ULCER, AND WAS ENDO-CLIPPED. TWO DAYS POST-OPERATIVE, THE PATIENT WAS ADMITTED TO A LOCAL HOSPITAL¿S INTENSIVE THERAPY UNIT WITH A MAJOR BLEED. THE PATIENT UNDERWENT ANOTHER RADIO FREQUENCY ABLATION ON THE (B)(6) TO TREAT (B)(6) OESOPHAGUS AND DEVELOPED ANOTHER MAJOR BLEED ON THE (B)(6), LEADING TO ANOTHER HOSPITAL ADMISSION. AS OF THE (B)(6), THE PATIENT WAS STILL IN THE INTENSIVE THERAPY UNIT. NOTHING ABNORMAL WAS NOTED DURING THE RADIO FREQUENCY ABLATION OR IMMEDIATELY AFTER THE PROCEDURE. A NEW CATHETER WAS USED FOR EACH ABLATION. THE TECHNIQUE USED TO ABLATE THE TISSUE WAS (B)(6) 2024 C10 M10 30-40 CM TREATED WITH CIRCUMFERENTIAL (APP, SCRA

    Patient problems: Hemorrhage/Blood Loss/Bleeding; Vomiting

    MAUDE report 20012315 ↗

Other Screw, Fixation, Intraosseous devices

All Screw, Fixation, Intraosseous devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page